Skip to main content

GENOMICA INTEGRATIVA DEL CANCER EN LA ERA DE LA SECUENCIACION MASIVA

SAF2012-36199

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2012
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Secretaría de Estado de Investigación, Desarrollo e Innovación
Beneficiary centre UNIVERSITAT POMPEU FABRA CCT

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma

  • Barneda Zahonero, Bruna
  • Collazo, Olga
  • Azagra Malo, Albert
  • Fernández Duran, Irene
  • Serra Musach, Jordi
  • Islam, Abul, 1978-
  • Vega García, Nerea
  • Malatesta, Roberta
  • Camós, Mireia
  • Gómez, Antonio
  • Román González, Lidia
  • Vidal, August
  • López Bigas, Núria
  • Villanueva, Alberto
  • Esteller, Manel
  • Parra, Maribel
The generation of B cells is a complex process requiring several cellular transitions, including cell commitment and differentiation. Proper transcriptional control to establish the genetic programs characteristic of each cellular stage is essential for the correct development of B lymphocytes. Deregulation of these particular transcriptional programs may result in a block in B-cell maturation, contributing to the development of hematological malignancies such as leukemia and lymphoma. However, very little is currently known about the role of transcriptional repressors in normal and aberrant B lymphopoiesis. Here we report that histone deacetylase 7 (HDAC7) is underexpressed in pro-B acute lymphoblastic leukemia (pro-B-ALL) and Burkitt lymphoma. Ectopic expression of HDAC7 induces apoptosis, leads to the downregulation of c-Myc and inhibits the oncogenic potential of cells in vivo, in a xenograft model. Most significantly, we have observed low levels of HDAC7 expression in B-ALL patient samples, which is correlated with the increased levels of c-Myc. From a mechanistic angle, we show that ectopically expressed HDAC7 localizes to the nucleus and interacts with the transcription factor myocyte enhancer factor C (MEF2C) and the corepressors HDAC3 and SMRT. Accordingly, both the HDAC7-MEF2C interaction domain as well as its catalytic domain are involved in the reduced cell viability induced by HDAC7. We conclude that HDAC7 has a potent anti-oncogenic effect on specific B-cell malignancies, indicating that its deregulation may contribute to the pathogenesis of the disease., This work was supported by a grant from the Spanish Ministry of Economy and Competitiveness (MINECO; SAF2011-28290; to MP). MP was supported by a Ramón y Cajal contract from the Spanish Ministry of Science and Innovation (MICIIN). LR-G was supported by an IDIBELL PhD fellowship. NL-B acknowledges the funding from MICIIN (SAF2012-36199).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action

  • Schroeder, Michael Philipp, 1986-
  • Rubio Pérez, Carlota, 1990-
  • Tamborero Noguera, David
  • González-Pérez, Abel
  • López Bigas, Núria
MOTIVATION: Several computational methods have been developed to identify cancer drivers genes-genes responsible for cancer development upon specific alterations. These alterations can cause the loss of function (LoF) of the gene product, for instance, in tumor suppressors, or increase or change its activity or function, if it is an oncogene. Distinguishing between these two classes is important to understand tumorigenesis in patients and has implications for therapy decision making. Here, we assess the capacity of multiple gene features related to the pattern of genomic alterations across tumors to distinguish between activating and LoF cancer genes, and we present an automated approach to aid the classification of novel cancer drivers according to their role. RESULT: /nOncodriveROLE is a machine learning-based approach that classifies driver genes according to their role, using several properties related to the pattern of alterations across tumors. The method shows an accuracy of 0.93 and Matthew's correlation coefficient of 0.84 classifying genes in the Cancer Gene Census. The OncodriveROLE classifier, its results when applied to two lists of predicted cancer drivers and TCGA-derived mutation and copy number features used by the classifier are available at http://bg.upf.edu/oncodrive-role. AVAILABILITY AND IMPLEMENTATION: The R implementation of the OncodriveROLE classifier is available at http://bg.upf.edu/oncodrive-role. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online., This work was supported by the Spanish Ministry of Economy and Competitivity (grant number SAF2012-36199) and the Spanish National Institute of Bioinformatics (INB). M.P.S. and C.R.-P. are supported by FPI fellowships
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Rational design of cancer gene panels with OncoPaD

  • Rubio Pérez, Carlota, 1990-
  • Déu Pons, Jordi
  • Tamborero Noguera, David
  • López Bigas, Núria
  • González-Pérez, Abel
BACKGROUND: Profiling the somatic mutations of genes which may inform about tumor evolution, prognostics and treatment is becoming a standard tool in clinical oncology. Commercially available cancer gene panels rely on manually gathered cancer-related genes, in a "one-size-fits-many" solution. The design of new panels requires laborious search of literature and cancer genomics resources, with their performance on cohorts of patients difficult to estimate. RESULTS: We present OncoPaD, to our knowledge the first tool aimed at the rational design of cancer gene panels. OncoPaD estimates the cost-effectiveness of the designed panel on a cohort of tumors and provides reports on the importance of individual mutations for tumorigenesis or therapy. With a friendly interface and intuitive input, OncoPaD suggests researchers relevant sets of genes to be included in the panel, because prior knowledge or analyses indicate that their mutations either drive tumorigenesis or function as biomarkers of drug response. OncoPaD also provides reports on the importance of individual mutations for tumorigenesis or therapy that support the interpretation of the results obtained with the designed panel. We demonstrate in silico that OncoPaD designed panels are more cost-effective-i.e. detect a maximum fraction of tumors in the cohort by sequencing a minimum quantity of DNA-than available panels. CONCLUSIONS: With its unique features, OncoPaD will help clinicians and researchers design tailored next-generating sequencing (NGS) panels to detect circulating tumor DNA or biopsy specimens, thereby facilitating early and accurate detection of tumors, genomics informed therapeutic decisions, patient follow-up and timely identification of resistance mechanisms to targeted agents. OncoPaD may be accessed through http://www.intogen.org/oncopad., A.G.-P. is supported by a Ramón y Cajal contract (RYC-2013-14554), which also funds the publication of this article. We also acknowledge funding from the Spanish Ministry of Economy and Competitiveness (grant no. SAF2012-36199), the Marató de TV3 Foundation, and the Spanish National Institute of Bioinformatics (INB). C.R.-P. is supported by an FPI fellowship. D.T. is supported by the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007- 2013) under REA grant agreement no. 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIÓ.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Cytoplasmic accumulation of NCoR in malignant melanoma: consequences of altered gene repression and prognostic significance

  • Gallardo Hernández, Fernando
  • Padrón, Andreina
  • Garcia Carbonell, Ricard
  • Rius, Cristina
  • González-Pérez, Abel
  • Arumí, Montserrat
  • Iglesias Coma, Mar
  • Nonell Mazelon, Lara, 1972-
  • Bellosillo Paricio, Beatriz
  • Segura Tigell, Sonia
  • Pujol Vallverdú, Ramón M.
  • López Bigas, Núria
  • Bertran, Joan
  • Bigas Salvans, Anna
  • Espinosa Blay, Lluís
Invasive malignant melanoma (MM) is an aggressive tumor with no curative therapy available in advanced stages. Nuclear corepressor (NCoR) is an essential regulator of gene transcription, and its function has been found deregulated in different types of cancer. In colorectal cancer cells, loss of nuclear NCoR is induced by Inhibitor of kappa B kinase (IKK) through the phosphorylation of specific serine residues. We here investigate whether NCoR function impacts in MM, which might have important diagnostic and prognostic significance. By IHC, we here determined the subcellular distribution of NCoR in a cohort of 63 primary invasive MM samples, and analyzed its possible correlation with specific clinical parameters. We therefore used a microarray-based strategy to determine global gene expression differences in samples with similar tumor stage, which differ in the presence of cytoplasmic or nuclear NCoR. We found that loss of nuclear NCoR results in upregulation of a specific cancer-related genetic signature, and is significantly associated with MM progression. Inhibition of IKK activity in melanoma cells reverts NCoR nuclear distribution and specific NCoR-regulated gene transcription. Analysis of public database demonstrated that inactivating NCoR mutations are highly prevalent in MM, showing features of driver oncogene., This work was supported by grants from AGAUR (SGR23), RTICCS/FEDER (RD12/0036/0054 and RD12/0036/0044), Spanish Ministry of Economy and Competitiveness (SAF2012-36199) and PI13/00448.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Comprehensive identification of mutational cancer driver genes across 12 tumor types

  • Tamborero Noguera, David
  • González-Pérez, Abel
  • Pérez Llamas, Christian, 1976-
  • Déu Pons, Jordi
  • Kandoth, Cyriac
  • Reimand, Jüri
  • Lawrence, Michael S.
  • Getz, Gad
  • Bader, Gary D.
  • Ding, Li
  • López Bigas, Núria
With the ability to fully sequence tumor genomes/exomes, the quest for cancer driver genes can now be undertaken in an unbiased manner. However, obtaining a complete catalog of cancer genes is difficult due to the heterogeneous molecular nature of the disease and the limitations of available computational methods. Here we show that the combination of complementary methods allows identifying a comprehensive and reliable list of cancer driver genes. We provide a list of 291 high-confidence cancer driver genes acting on 3,205 tumors from 12 different cancer types. Among those genes, some have not been previously identified as cancer drivers and 16 have clear preference to sustain mutations in one specific tumor type. The novel driver candidates complement our current picture of the emergence of these diseases. In summary, the catalog of driver genes and the methodology presented here open new avenues to better understand the mechanisms of tumorigenesis., We acknowledge funding from the Spanish Ministry of Science and Technology (grant number SAF2009-06954 and SAF2012-36199) and the Spanish National Institute of Bioinformatics (INB). This work was supported by NRNB (U.S. National Institutes of Health, National Center for Research Resources grant number P41 GM103504). We gratefully acknowledge the contributions from the TCGA Research Network and its TCGA Pan-Cancer Analysis Working Group (contributing consortium members are listed in Supplementary Note 1).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities

  • Rubio Pérez, Carlota, 1990-
  • Tamborero Noguera, David
  • Schroeder, Michael Philipp, 1986-
  • Antolín Hernández, Albert, 1984-
  • Déu Pons, Jordi
  • Pérez Llamas, Christian, 1976-
  • Mestres i López, Jordi
  • González-Pérez, Abel
  • López Bigas, Núria
Large efforts dedicated to detect somatic alterations across tumor genomes/exomes are expected to produce significant improvements in precision cancer medicine. However, high inter-tumor heterogeneity is a major obstacle to developing and applying therapeutic targeted agents to treat most cancer patients. Here, we offer a comprehensive assessment of the scope of targeted therapeutic agents in a large pan-cancer cohort. We developed an in silico prescription strategy based on identification of the driver alterations in each tumor and their druggability options. Although relatively few tumors are tractable by approved agents following clinical guidelines (5.9%), up to 40.2% could benefit from different repurposing options, and up to 73.3% considering treatments currently under clinical investigation. We also identified 80 therapeutically targetable cancer genes., We acknowledge funding from the Spanish Ministry of Economy and Competitiveness (grant number SAF2012-36199), La Fundació la Marató de TV3, and the Spanish National Institute of Bioinformatics (INB). C.R.-P. and M.P.S. are supported by an FPI fellowship. D.T. is supported by the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007-2013) under REA grant agreement number 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIÓ. A.G.-P. is supported by a Ramón y Cajal contract.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA polymerase II CTD kinase

  • Vona, Chiara Di
  • Bezdan, Daniela
  • Islam, Abul, 1978-
  • Salichs Fradera, Eulàlia
  • López Bigas, Núria
  • Ossowski, Stephan
  • Luna, Susana de la
DYRK1A is a dosage-sensitive protein kinase that fulfills key roles during development and in tissue homeostasis, and its dysregulation results in human pathologies. DYRK1A is present in both the nucleus and cytoplasm of mammalian cells, although its nuclear function remains unclear. Genome-wide analysis of DYRK1A-associated loci reveals that the kinase is recruited preferentially to promoters of genes actively transcribed by RNA polymerase II (RNAPII), which are functionally associated with translation, RNA processing, and cell cycle. DYRK1A-bound promoter sequences are highly enriched in a conserved palindromic motif, which is necessary to drive DYRK1A-dependent transcriptional activation. DYRK1A phosphorylates the C-terminal domain (CTD) of RNAPII at Ser2 and Ser5. Depletion of DYRK1A results in reduced association of RNAPII at the target promoters as well as hypophosphorylation of the RNAPII CTD along the target gene bodies. These results are consistent with DYRK1A being a transcriptional regulator by acting as a CTD kinase., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO: BFU2010-15347, BFU2013-44513 to S.d.l.L., SAF2012-36199 to N.L.-B., and ‘Centro de Excelencia Severo Ochoa 2013-2017’-SEV-2012-0208) and the Secretariat of Universities and Research-Government of Catalonia (2014SGR674 to S.d.l.L.). C.D.V. and E.S. were FPI predoctoral fellows financed by MINECO (BES2008-002751 and BES2005-10136)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

IntOGen-mutations identifies cancer drivers across tumor types

  • Gonzalez-Perez, Abel
  • Pérez Llamas, Christian, 1976-
  • Deu Pons, Jordi
  • Tamborero Noguera, David
  • Schroeder, Michael Philipp,1986-
  • Jené i Sanz, Alba, 1984-
  • Santos, Alberto
  • López Bigas, Núria
Includes supplementary materials for the online appendix., The IntOGen-mutations platform (http://www.intogen.org/mutations/) summarizes somatic mutations, genes and pathways involved in tumorigenesis. It identifies and visualizes cancer drivers, analyzing 4,623 exomes from 13 cancer sites. It provides support to cancer researchers, aids the identification of drivers across tumor cohorts and helps rank mutations for better clinical decision-making., We acknowledge funding from the Spanish Ministry of Economy and Competitivity (grants SAF2009-06954 and SAF2012-36199) and the Spanish National Institute of Bioinformatics (INB). We gratefully acknowledge contributions from the TCGA Research Network and its TCGA Pan-Cancer Analysis Working Group (contributing consortium members are listed in Supplementary Note 5). The TCGA Pan-Cancer Analysis Working Group is coordinated by J.M. Stuart, C. Sander and I. Shmulevich. We are also grateful to the ICGC for the tumor genome resequencing data generated.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The mutational landscape of chromatin regulatory factors across 4,623 tumor samples

  • González-Pérez, Abel
  • Jené i Sanz, Alba, 1984-
  • López Bigas, Núria
Background: Chromatin regulatory factors are emerging as important genes in cancer development and are regarded as interesting candidates for novel targets for cancer treatment. However, we lack a comprehensive understanding of the role of this group of genes in different cancer types. Results: We have analyzed 4,623 tumor samples from thirteen anatomical sites to determine which chromatin regulatory factors are candidate drivers in these different sites. We identify 34 chromatin regulatory factors that are likely drivers in tumors from at least one site, all with relatively low mutational frequency. We also analyze the relative importance of mutations in this group of genes for the development of tumorigenesis in each site, and in different tumor types from the same site. Conclusions: We find that, although tumors from all thirteen sites show mutations in likely driver chromatin regulatory factors, these are more prevalent in tumors arising from certain tissues. With the exception of hematopoietic, liver and kidney tumors, as a median, the mutated factors are less than one fifth of all mutated drivers across all sites analyzed. We also show that mutations in two of these genes, MLL and EP300, correlate with broad expression changes across cancer cell lines, thus presenting at least one mechanism through which these mutations could contribute to tumorigenesis in cells of the corresponding tissues., We acknowledge funding from the Spanish Ministry of Economy and Competitivity (grant numbers SAF2009-06954 and SAF2012-36199) and the Spanish National Institute of Bioinformatics. AJ-S is supported by an FPI fellowship
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Mapping of six somatic linker histone H1 variants in human breast cancer cells uncovers specific features of H1.2

  • Millán Ariño, Lluís, 1984-
  • Islam, Abul, 1978-
  • Izquierdo Bouldstridge, Andrea
  • Mayor, Regina
  • Terme, Jean Michel
  • Luque, Neus
  • Sancho Medina, Mónica
  • López Bigas, Núria
  • Jordan Vallès, Albert
Seven linker histone H1 variants are present in human somatic cells with distinct prevalence across cell types. Despite being key structural components of chromatin, it is not known whether the different variants have specific roles in the regulation of nuclear processes or are differentially distributed throughout the genome. Using variant-specific antibodies to H1 and hemagglutinin (HA)-tagged recombinant H1 variants expressed in breast cancer cells, we have investigated the distribution of six H1 variants in promoters and genome-wide. H1 is depleted at promoters depending on its transcriptional status and differs between variants. Notably, H1.2 is less abundant than other variants at the transcription start sites of inactive genes, and promoters enriched in H1.2 are different from those enriched in other variants and tend to be repressed. Additionally, H1.2 is enriched at chromosomal domains characterized by low guanine–cytosine (GC) content and is associated with lamina-associated domains. Meanwhile, other variants are associated with higher GC content, CpG islands and gene-rich domains. For instance, H1.0 and H1X are enriched at gene-rich chromosomes, whereas H1.2 is depleted. In short, histone H1 is not uniformly distributed along the genome and there are differences between variants, H1.2 being the one showing the most specific pattern and strongest correlation with low gene expression., Ministerio de Ciencia e Innovació n of Spain (MICINN) and FEDER [BFU2011-23057 to A.J.]; Ministerio de Economía y Competitividad [SAF2012-36199 to N.L.-B.]; Generalitat de Catalunya [2009-SGR-1222 to A.J.]; JAE-Doc contract from CSIC-MICINN (to J.-M.T.); TA contract from CSIC-MICINN (to R.M.); FPU predoctoral fellowship from MICINN (to L.M.-A.). Funding for open access charge: Ministerio de Ciencia e Innovación of Spain (MICINN) and FEDER [BFU2011-23057 to A.J.]
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cytoplasmic accumulation of NCoR in malignant melanoma: consequences of altered gene repression and prognostic significance

  • Gallardo Hernández, Fernando
  • Padrón, Andreina
  • Garcia Carbonell, Ricard
  • Rius, Cristina
  • González-Pérez, Abel
  • Arumí, Montserrat
  • Iglesias Coma, Mar
  • Nonell Mazelon, Lara, 1972-
  • Bellosillo Paricio, Beatriz
  • Segura Tigell, Sonia
  • Pujol Vallverdú, Ramón M.
  • López Bigas, Núria
  • Bertran, Joan
  • Bigas Salvans, Anna
  • Espinosa Blay, Lluís
Invasive malignant melanoma (MM) is an aggressive tumor with no curative therapy available in advanced stages. Nuclear corepressor (NCoR) is an essential regulator of gene transcription, and its function has been found deregulated in different types of cancer. In colorectal cancer cells, loss of nuclear NCoR is induced by Inhibitor of kappa B kinase (IKK) through the phosphorylation of specific serine residues. We here investigate whether NCoR function impacts in MM, which might have important diagnostic and prognostic significance. By IHC, we here determined the subcellular distribution of NCoR in a cohort of 63 primary invasive MM samples, and analyzed its possible correlation with specific clinical parameters. We therefore used a microarray-based strategy to determine global gene expression differences in samples with similar tumor stage, which differ in the presence of cytoplasmic or nuclear NCoR. We found that loss of nuclear NCoR results in upregulation of a specific cancer-related genetic signature, and is significantly associated with MM progression. Inhibition of IKK activity in melanoma cells reverts NCoR nuclear distribution and specific NCoR-regulated gene transcription. Analysis of public database demonstrated that inactivating NCoR mutations are highly prevalent in MM, showing features of driver oncogene., This work was supported by grants from AGAUR (SGR23), RTICCS/FEDER (RD12/0036/0054 and RD12/0036/0044), Spanish Ministry of Economy and Competitiveness (SAF2012-36199) and PI13/00448.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Rational design of cancer gene panels with OncoPaD

  • Rubio Pérez, Carlota, 1990-
  • Déu Pons, Jordi
  • Tamborero Noguera, David
  • López Bigas, Núria
  • González-Pérez, Abel
BACKGROUND: Profiling the somatic mutations of genes which may inform about tumor evolution, prognostics and treatment is becoming a standard tool in clinical oncology. Commercially available cancer gene panels rely on manually gathered cancer-related genes, in a "one-size-fits-many" solution. The design of new panels requires laborious search of literature and cancer genomics resources, with their performance on cohorts of patients difficult to estimate. RESULTS: We present OncoPaD, to our knowledge the first tool aimed at the rational design of cancer gene panels. OncoPaD estimates the cost-effectiveness of the designed panel on a cohort of tumors and provides reports on the importance of individual mutations for tumorigenesis or therapy. With a friendly interface and intuitive input, OncoPaD suggests researchers relevant sets of genes to be included in the panel, because prior knowledge or analyses indicate that their mutations either drive tumorigenesis or function as biomarkers of drug response. OncoPaD also provides reports on the importance of individual mutations for tumorigenesis or therapy that support the interpretation of the results obtained with the designed panel. We demonstrate in silico that OncoPaD designed panels are more cost-effective-i.e. detect a maximum fraction of tumors in the cohort by sequencing a minimum quantity of DNA-than available panels. CONCLUSIONS: With its unique features, OncoPaD will help clinicians and researchers design tailored next-generating sequencing (NGS) panels to detect circulating tumor DNA or biopsy specimens, thereby facilitating early and accurate detection of tumors, genomics informed therapeutic decisions, patient follow-up and timely identification of resistance mechanisms to targeted agents. OncoPaD may be accessed through http://www.intogen.org/oncopad., A.G.-P. is supported by a Ramón y Cajal contract (RYC-2013-14554), which also funds the publication of this article. We also acknowledge funding from the Spanish Ministry of Economy and Competitiveness (grant no. SAF2012-36199), the Marató de TV3 Foundation, and the Spanish National Institute of Bioinformatics (INB). C.R.-P. is supported by an FPI fellowship. D.T. is supported by the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007- 2013) under REA grant agreement no. 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIÓ.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

IntOGen-mutations identifies cancer drivers across tumor types

  • Gonzalez-Perez, Abel
  • Pérez Llamas, Christian, 1976-
  • Deu Pons, Jordi
  • Tamborero Noguera, David
  • Schroeder, Michael Philipp,1986-
  • Jené i Sanz, Alba, 1984-
  • Santos, Alberto
  • López Bigas, Núria
Includes supplementary materials for the online appendix., The IntOGen-mutations platform (http://www.intogen.org/mutations/) summarizes somatic mutations, genes and pathways involved in tumorigenesis. It identifies and visualizes cancer drivers, analyzing 4,623 exomes from 13 cancer sites. It provides support to cancer researchers, aids the identification of drivers across tumor cohorts and helps rank mutations for better clinical decision-making., We acknowledge funding from the Spanish Ministry of Economy and Competitivity (grants SAF2009-06954 and SAF2012-36199) and the Spanish National Institute of Bioinformatics (INB). We gratefully acknowledge contributions from the TCGA Research Network and its TCGA Pan-Cancer Analysis Working Group (contributing consortium members are listed in Supplementary Note 5). The TCGA Pan-Cancer Analysis Working Group is coordinated by J.M. Stuart, C. Sander and I. Shmulevich. We are also grateful to the ICGC for the tumor genome resequencing data generated.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action

  • Schroeder, Michael Philipp, 1986-
  • Rubio Pérez, Carlota, 1990-
  • Tamborero Noguera, David
  • González-Pérez, Abel
  • López Bigas, Núria
MOTIVATION: Several computational methods have been developed to identify cancer drivers genes-genes responsible for cancer development upon specific alterations. These alterations can cause the loss of function (LoF) of the gene product, for instance, in tumor suppressors, or increase or change its activity or function, if it is an oncogene. Distinguishing between these two classes is important to understand tumorigenesis in patients and has implications for therapy decision making. Here, we assess the capacity of multiple gene features related to the pattern of genomic alterations across tumors to distinguish between activating and LoF cancer genes, and we present an automated approach to aid the classification of novel cancer drivers according to their role. RESULT: /nOncodriveROLE is a machine learning-based approach that classifies driver genes according to their role, using several properties related to the pattern of alterations across tumors. The method shows an accuracy of 0.93 and Matthew's correlation coefficient of 0.84 classifying genes in the Cancer Gene Census. The OncodriveROLE classifier, its results when applied to two lists of predicted cancer drivers and TCGA-derived mutation and copy number features used by the classifier are available at http://bg.upf.edu/oncodrive-role. AVAILABILITY AND IMPLEMENTATION: The R implementation of the OncodriveROLE classifier is available at http://bg.upf.edu/oncodrive-role. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online., This work was supported by the Spanish Ministry of Economy and Competitivity (grant number SAF2012-36199) and the Spanish National Institute of Bioinformatics (INB). M.P.S. and C.R.-P. are supported by FPI fellowships
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA polymerase II CTD kinase

  • Vona, Chiara Di
  • Bezdan, Daniela
  • Islam, Abul, 1978-
  • Salichs Fradera, Eulàlia
  • López Bigas, Núria
  • Ossowski, Stephan
  • Luna, Susana de la
DYRK1A is a dosage-sensitive protein kinase that fulfills key roles during development and in tissue homeostasis, and its dysregulation results in human pathologies. DYRK1A is present in both the nucleus and cytoplasm of mammalian cells, although its nuclear function remains unclear. Genome-wide analysis of DYRK1A-associated loci reveals that the kinase is recruited preferentially to promoters of genes actively transcribed by RNA polymerase II (RNAPII), which are functionally associated with translation, RNA processing, and cell cycle. DYRK1A-bound promoter sequences are highly enriched in a conserved palindromic motif, which is necessary to drive DYRK1A-dependent transcriptional activation. DYRK1A phosphorylates the C-terminal domain (CTD) of RNAPII at Ser2 and Ser5. Depletion of DYRK1A results in reduced association of RNAPII at the target promoters as well as hypophosphorylation of the RNAPII CTD along the target gene bodies. These results are consistent with DYRK1A being a transcriptional regulator by acting as a CTD kinase., This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO: BFU2010-15347, BFU2013-44513 to S.d.l.L., SAF2012-36199 to N.L.-B., and ‘Centro de Excelencia Severo Ochoa 2013-2017’-SEV-2012-0208) and the Secretariat of Universities and Research-Government of Catalonia (2014SGR674 to S.d.l.L.). C.D.V. and E.S. were FPI predoctoral fellows financed by MINECO (BES2008-002751 and BES2005-10136)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma

  • Barneda Zahonero, Bruna
  • Collazo, Olga
  • Azagra Malo, Albert
  • Fernández Duran, Irene
  • Serra Musach, Jordi
  • Islam, Abul, 1978-
  • Vega García, Nerea
  • Malatesta, Roberta
  • Camós, Mireia
  • Gómez, Antonio
  • Román González, Lidia
  • Vidal, August
  • López Bigas, Núria
  • Villanueva, Alberto
  • Esteller, Manel
  • Parra, Maribel
The generation of B cells is a complex process requiring several cellular transitions, including cell commitment and differentiation. Proper transcriptional control to establish the genetic programs characteristic of each cellular stage is essential for the correct development of B lymphocytes. Deregulation of these particular transcriptional programs may result in a block in B-cell maturation, contributing to the development of hematological malignancies such as leukemia and lymphoma. However, very little is currently known about the role of transcriptional repressors in normal and aberrant B lymphopoiesis. Here we report that histone deacetylase 7 (HDAC7) is underexpressed in pro-B acute lymphoblastic leukemia (pro-B-ALL) and Burkitt lymphoma. Ectopic expression of HDAC7 induces apoptosis, leads to the downregulation of c-Myc and inhibits the oncogenic potential of cells in vivo, in a xenograft model. Most significantly, we have observed low levels of HDAC7 expression in B-ALL patient samples, which is correlated with the increased levels of c-Myc. From a mechanistic angle, we show that ectopically expressed HDAC7 localizes to the nucleus and interacts with the transcription factor myocyte enhancer factor C (MEF2C) and the corepressors HDAC3 and SMRT. Accordingly, both the HDAC7-MEF2C interaction domain as well as its catalytic domain are involved in the reduced cell viability induced by HDAC7. We conclude that HDAC7 has a potent anti-oncogenic effect on specific B-cell malignancies, indicating that its deregulation may contribute to the pathogenesis of the disease., This work was supported by a grant from the Spanish Ministry of Economy and Competitiveness (MINECO; SAF2011-28290; to MP). MP was supported by a Ramón y Cajal contract from the Spanish Ministry of Science and Innovation (MICIIN). LR-G was supported by an IDIBELL PhD fellowship. NL-B acknowledges the funding from MICIIN (SAF2012-36199).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Mapping of six somatic linker histone H1 variants in human breast cancer cells uncovers specific features of H1.2

  • Millán Ariño, Lluís, 1984-
  • Islam, Abul, 1978-
  • Izquierdo Bouldstridge, Andrea
  • Mayor, Regina
  • Terme, Jean Michel
  • Luque, Neus
  • Sancho Medina, Mónica
  • López Bigas, Núria
  • Jordan Vallès, Albert
Seven linker histone H1 variants are present in human somatic cells with distinct prevalence across cell types. Despite being key structural components of chromatin, it is not known whether the different variants have specific roles in the regulation of nuclear processes or are differentially distributed throughout the genome. Using variant-specific antibodies to H1 and hemagglutinin (HA)-tagged recombinant H1 variants expressed in breast cancer cells, we have investigated the distribution of six H1 variants in promoters and genome-wide. H1 is depleted at promoters depending on its transcriptional status and differs between variants. Notably, H1.2 is less abundant than other variants at the transcription start sites of inactive genes, and promoters enriched in H1.2 are different from those enriched in other variants and tend to be repressed. Additionally, H1.2 is enriched at chromosomal domains characterized by low guanine–cytosine (GC) content and is associated with lamina-associated domains. Meanwhile, other variants are associated with higher GC content, CpG islands and gene-rich domains. For instance, H1.0 and H1X are enriched at gene-rich chromosomes, whereas H1.2 is depleted. In short, histone H1 is not uniformly distributed along the genome and there are differences between variants, H1.2 being the one showing the most specific pattern and strongest correlation with low gene expression., Ministerio de Ciencia e Innovació n of Spain (MICINN) and FEDER [BFU2011-23057 to A.J.]; Ministerio de Economía y Competitividad [SAF2012-36199 to N.L.-B.]; Generalitat de Catalunya [2009-SGR-1222 to A.J.]; JAE-Doc contract from CSIC-MICINN (to J.-M.T.); TA contract from CSIC-MICINN (to R.M.); FPU predoctoral fellowship from MICINN (to L.M.-A.). Funding for open access charge: Ministerio de Ciencia e Innovación of Spain (MICINN) and FEDER [BFU2011-23057 to A.J.]
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comprehensive identification of mutational cancer driver genes across 12 tumor types

  • Tamborero Noguera, David
  • González-Pérez, Abel
  • Pérez Llamas, Christian, 1976-
  • Déu Pons, Jordi
  • Kandoth, Cyriac
  • Reimand, Jüri
  • Lawrence, Michael S.
  • Getz, Gad
  • Bader, Gary D.
  • Ding, Li
  • López Bigas, Núria
With the ability to fully sequence tumor genomes/exomes, the quest for cancer driver genes can now be undertaken in an unbiased manner. However, obtaining a complete catalog of cancer genes is difficult due to the heterogeneous molecular nature of the disease and the limitations of available computational methods. Here we show that the combination of complementary methods allows identifying a comprehensive and reliable list of cancer driver genes. We provide a list of 291 high-confidence cancer driver genes acting on 3,205 tumors from 12 different cancer types. Among those genes, some have not been previously identified as cancer drivers and 16 have clear preference to sustain mutations in one specific tumor type. The novel driver candidates complement our current picture of the emergence of these diseases. In summary, the catalog of driver genes and the methodology presented here open new avenues to better understand the mechanisms of tumorigenesis., We acknowledge funding from the Spanish Ministry of Science and Technology (grant number SAF2009-06954 and SAF2012-36199) and the Spanish National Institute of Bioinformatics (INB). This work was supported by NRNB (U.S. National Institutes of Health, National Center for Research Resources grant number P41 GM103504). We gratefully acknowledge the contributions from the TCGA Research Network and its TCGA Pan-Cancer Analysis Working Group (contributing consortium members are listed in Supplementary Note 1).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities

  • Rubio Pérez, Carlota, 1990-
  • Tamborero Noguera, David
  • Schroeder, Michael Philipp, 1986-
  • Antolín Hernández, Albert, 1984-
  • Déu Pons, Jordi
  • Pérez Llamas, Christian, 1976-
  • Mestres i López, Jordi
  • González-Pérez, Abel
  • López Bigas, Núria
Large efforts dedicated to detect somatic alterations across tumor genomes/exomes are expected to produce significant improvements in precision cancer medicine. However, high inter-tumor heterogeneity is a major obstacle to developing and applying therapeutic targeted agents to treat most cancer patients. Here, we offer a comprehensive assessment of the scope of targeted therapeutic agents in a large pan-cancer cohort. We developed an in silico prescription strategy based on identification of the driver alterations in each tumor and their druggability options. Although relatively few tumors are tractable by approved agents following clinical guidelines (5.9%), up to 40.2% could benefit from different repurposing options, and up to 73.3% considering treatments currently under clinical investigation. We also identified 80 therapeutically targetable cancer genes., We acknowledge funding from the Spanish Ministry of Economy and Competitiveness (grant number SAF2012-36199), La Fundació la Marató de TV3, and the Spanish National Institute of Bioinformatics (INB). C.R.-P. and M.P.S. are supported by an FPI fellowship. D.T. is supported by the People Programme (Marie Curie Actions) of the Seventh Framework Programme of the European Union (FP7/2007-2013) under REA grant agreement number 600388 and by the Agency of Competitiveness for Companies of the Government of Catalonia, ACCIÓ. A.G.-P. is supported by a Ramón y Cajal contract.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The mutational landscape of chromatin regulatory factors across 4,623 tumor samples

  • González-Pérez, Abel
  • Jené i Sanz, Alba, 1984-
  • López Bigas, Núria
Background: Chromatin regulatory factors are emerging as important genes in cancer development and are regarded as interesting candidates for novel targets for cancer treatment. However, we lack a comprehensive understanding of the role of this group of genes in different cancer types. Results: We have analyzed 4,623 tumor samples from thirteen anatomical sites to determine which chromatin regulatory factors are candidate drivers in these different sites. We identify 34 chromatin regulatory factors that are likely drivers in tumors from at least one site, all with relatively low mutational frequency. We also analyze the relative importance of mutations in this group of genes for the development of tumorigenesis in each site, and in different tumor types from the same site. Conclusions: We find that, although tumors from all thirteen sites show mutations in likely driver chromatin regulatory factors, these are more prevalent in tumors arising from certain tissues. With the exception of hematopoietic, liver and kidney tumors, as a median, the mutated factors are less than one fifth of all mutated drivers across all sites analyzed. We also show that mutations in two of these genes, MLL and EP300, correlate with broad expression changes across cancer cell lines, thus presenting at least one mechanism through which these mutations could contribute to tumorigenesis in cells of the corresponding tissues., We acknowledge funding from the Spanish Ministry of Economy and Competitivity (grant numbers SAF2009-06954 and SAF2012-36199) and the Spanish National Institute of Bioinformatics. AJ-S is supported by an FPI fellowship